Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Third Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces $100 Million Registered Direct Offering
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports First Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.